Tag: DiscGenics

Cell therapy IDCT passes initial safety review of first-in-human clinical trial...

It has been announced that IDCT (DiscGenics) has passed the initial planned safety review of its Phase I/II trial evaluating the allogeneic, injectable disc...

Clinical evaluation of non-surgical degenerative disc disease treatment to begin in...

The Japanese Pharmaceuticals and Medical Devices Agency (PMDA) has approved a Clinical Trial Notification (CTN) application for IDCT (DiscGenics), an allogenic injectable disc cell...

First patient treated in US clinical trial of IDCT for degenerative...

DiscGenics, a clinical stage regenerative medicine company, has announced the first patient has been treated in its phase I/II US clinical trial of IDCT...
DiscGenics logo

DiscGenics’ IDCT Investigational New Drug application accepted by US FDA

DiscGenics has been notified by the US Food and Drug Administration (FDA) that an Investigational New Drug (IND) application for a clinical study of...

DiscGenics granted 9 new patents for DiscoGenic Cell technology

DiscGenics has been granted 9 new patents, expanding its intellectual property portfolio within both the US and globally to 24 issued patents. The new...